

Ledipasvir

产品编号: D51075

CAS: 1256388-51-8

分子式: C₄₉H₅₄F₂N₈O₆

纯度: ≥98%

InChi: InChI=1S/C₄₉H₅₄F₂N₈O₆/c1-24(2)39(56-46(62)64-5)44(60)58-23-48(15-16-48)21-38(58)42-52-22-37(55-42)28-9-13-32-31-12-8-26(18-33(31)49(50,51)34(32)19-28)27-10-14-35-36(20-27)54-43(53-35)41-29-7-11-30(17-29)59(41)45(61)40(25(3)4)57-47(63)65-6/h8-10,12-14,18-20,22,24-25,29-30,38-41H,7,11,15-17,21,23H2,1-6H3,(H,52,55)(H,53,54)(H,56,62)(H,57,63)/t29-,30+,38-,39-,40-,41-/m0/s1

InChi Key: VRTWBAAJJOHBQU-KMWAZVGDSA-N

Smiles: CC(C)[C@H](NC(=O)OC)C(=O)N1CC2(C[C@H]1C1NC(=CN=1)C1=CC3=C(C=C1)C1=CC=C(C=C1C3(F)F)C1=CC3NC(=NC=3C=C1)[C@@H]1[C@@H]3C[C@@H](CC3)N1C(=O)[C@@H](NC(=O)OC)C(C)C)CC2

外观: 固体粉末

作用通路: HCV

溶解性: Solubility (25°C) DMSO: 100 mg/mL(112.48 mM). Water: Insoluble.

保存条件: Store in dry, dark place for one year.

产品介绍: Ledipasvir, also known as GS-5885; is an inhibitor of the hepatitis C virus NS5A protein and is a drug for the treatment of hepatitis C that was developed by Gilead Sciences. On October 10, 2014 the FDA approved the combination product ledipasvir 90 mg/sofosbuvir 400 mg (trade name Harvoni). The ledipasvir/sofosbuvir combination is a direct-acting antiviral agent that interferes with HCV replication and can be used to treat patients with genotypes 1a or 1b without PEG-interferon or ribavirin. (<http://en.wikipedia.org/wiki/Ledipasvir>)